Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Post by Bullknit101on Jan 02, 2021 6:55pm
164 Views
Post# 32210287

CB1 Capital - Are they still on board?

CB1 Capital - Are they still on board?2 years ago but still relevant, since we are now in the transitional year. Interview on Midas Letter with CB1's Todd Harrison, quote: " James West: Interesting. So are there any names you can with us of up-and-coming companies that youre particularly excited about? Todd Harrison: Well, on the biotech side, GW, I talked about Corbus, were big fans of. I mean, theres a few others; on a biosythentic side, theres a company called InMed Pharmaceuticals, which is early, right, pre-clinical, but its a biosythentic, and we think the trend is really going to move towards biosythentics, away from the more traditional farming side. So whenever we look at investments, with the exception of Village Farms, which we think is a unique situation given their US and Mexican optionality, we really try to steer clear of the pure cultivators, because we think the farming side is probably the least sexy side of the equation, right?"
<< Previous
Bullboard Posts
Next >>